Pathological assessment of chronic kidney disease with DWI : Is there an added value for diffusion kurtosis imaging?

2021 ◽  
Author(s):  
Wei Mao ◽  
Yuqin Ding ◽  
Xiaoqiang Ding ◽  
Yaqiong Wang ◽  
Caixia Fu ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Added Value ◽  
Diffusion Kurtosis Imaging ◽  
Diffusion Kurtosis ◽  
Pathological Assessment

Staging liver fibrosis with DWI: is there an added value for diffusion kurtosis imaging?

2018 ◽  
Vol 28 (7) ◽  
pp. 3041-3049 ◽  
Author(s):  
Li Yang ◽  
Shengxiang Rao ◽  
Wentao Wang ◽  
Caizhong Chen ◽  
Ying Ding ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Added Value ◽  
Diffusion Kurtosis Imaging ◽  
Diffusion Kurtosis

scholarly journals Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease

2017 ◽  
Vol 46 (1) ◽  
pp. 73-81 ◽  
Author(s):  
Farsad Afshinnia ◽  
Lixia Zeng ◽  
Jaeman Byun ◽  
Crystal A. Gadegbeku ◽  
Maria Chiara Magnone ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Chronic Kidney Disease ◽  
Coronary Artery ◽  
Kidney Disease ◽  
Added Value ◽  
Enzyme Linked Immunosorbent Assay ◽  
Specific Product ◽  
Ckd Stage ◽  
Artery Disease ◽  
Stage 1

Background: The role of myeloperoxidase in chronic kidney disease (CKD) and its association with coronary artery disease (CAD) is controversial. In this study, we compared myeloperoxidase and protein-bound 3-chlorotyrosine (ClY) levels in subjects with varying degrees of CKD and tested their associations with CAD. Methods: From Clinical Phenotyping Resource and Biobank Core, 111 patients were selected from CKD stages 1 to 5. Plasma myeloperoxidase level was measured using enzyme-linked-immunosorbent assay. Plasma protein-bound 3-ClY, a specific product of hypochlorous acid generated by myeloperoxidase was measured by liquid chromatography mass spectrometry. Results: We selected 29, 20, 24, 22, and 16 patients from stages 1 to 5 CKD, respectively. In a sex-adjusted general linear model, mean ± SD of myeloperoxidase levels decreased from 18.1 ± 12.3 pmol in stage 1 to 10.9 ± 4.7 pmol in stage 5 (p = 0.011). In patients with and without CAD, the levels were 19.1 ± 10.1 and 14.8 ± 8.7 pmol (p = 0.036). There was an increase in 3-ClY mean from 0.81 ± 0.36 mmol/mol-tyrosine in stage 1 to 1.42 ± 0.41 mmol/mol-tyrosine in stage 5 (p < 0.001). The mean 3-ClY levels in patients with and without CAD were 1.25 ± 0.44 and 1.04 ± 0.42 mmol/mol-tyrosine (p = 0.023), respectively. C-statistic of ClY when added to myeloperoxidase level to predict CKD stage 5 was 0.86, compared to 0.79 for the myeloperoxidase level alone (p = 0.0097). Conclusion: The myeloperoxidase levels decrease from stages 1 to 5, whereas activity increases. In contrast, both myeloperoxidase and ClY levels rise in the presence of CAD at various stages of CKD. Measuring both plasma myeloperoxidase and 3-CLY levels provide added value to determine the burden of myeloperoxidase-mediated oxidative stress.

scholarly journals sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Maëlle Plawecki ◽  
Marion Morena ◽  
Nils Kuster ◽  
Leila Chenine ◽  
Hélène Leray-Moragues ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Risk Stratification ◽  
Risk Prediction ◽  
Natriuretic Peptides ◽  
Cardiac Remodeling ◽  
Left Ventricular ◽  
Added Value ◽  
Volume Index

Heart failure is the most frequent cardiac complication of chronic kidney disease (CKD). Biomarkers help identify high-risk patients. Natriuretic peptides (BNP and NT-proBNP) are largely used for monitoring patients with cardiac failure but are highly dependent on glomerular filtration rate (GFR). Soluble suppression of tumorigenicity 2 (sST2) biomarker is well identified in risk stratification of cardiovascular (CV) events in heart failure. Furthermore, sST2 is included in a bioclinical score to stratify mortality risk. The aims of this study were to evaluate (i) the interest of circulating sST2 level in heart dysfunction and (ii) the bioclinical score (Barcelona Bio-Heart Failure risk calculator) to predict the risk of composite outcome (major adverse coronary events) and mortality in the CKD population. A retrospective study was carried out on 218 CKD patients enrolled from 2004 to 2015 at Montpellier University Hospital. sST2 was measured by ELISA (Presage ST2® kit). GFR was estimated by the CKD-EPI equation (eGFR). Indices of cardiac parameters were performed by cardiac echography. No patient had reduced ejection fraction. 112 patients had left ventricular hypertrophy, and 184 presented cardiac dysfunction, with structural, functional abnormalities or both. sST2 was independent of age and eGFR (ρ=0.05, p=0.44, and ρ=−0.07, p=0.3, respectively). Regarding echocardiogram data, sST2 was correlated with left ventricular mass index (ρ=0.16, p=0.02), left atrial diameter (ρ=0.14, p=0.04), and volume index (ρ=0.13, p=0.05). sST2 alone did not change risk prediction of death and/or CV events compared to natriuretic peptides. Included in the Barcelona Bio-Heart Failure (BCN Bio-HF) score, sST2 added value and better stratified the risk of CV events and/or death in CKD patients (p<0.0001). To conclude, sST2 was associated with cardiac remodeling independently of eGFR, unlike other cardiac biomarkers. Added to the BCN Bio-HF score, the risk stratification of death and/or CV events in nondialyzed CKD patients was highly improved.

scholarly journals Diagnostic utility of FGF-23 in mineral bone disorder during chronic kidney disease

2022 ◽  
Vol 11 ◽  
pp. 1-4
Author(s):  
Luisa Albanese ◽  
Gemma Caliendo ◽  
Giovanna D'Elia ◽  
Luana Passariello ◽  
Anna Maria Molinari ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Fibroblast Growth Factor 23 ◽  
Added Value ◽  
Automated Method ◽  
Mineral Bone Disorder ◽  
Bone Disorder ◽  
Advanced Stages ◽  
25 Oh Vitamin D ◽  
Fgf 23

Our data confirm that intact fibroblast growth factor 23 (iFGF-23) concentration is increased in patients with chronic kidney disease (CKD) and that it increases with disease progression (stages I-V). Therefore, iFGF-23 could be considered an early biomarker in the course of chronic kidney disease-mineral bone disorder (CKD-MBD), which has several aspects that make it potentially useful in clinical practice. The availability of an automated method for iFGF-23 assay may represent an added value in the management of the patient with CKD-MBD already from the early stages of the disease, before the increase of the routinely used laboratory parameters, 1-84 parathyroid hormone (PTH) and 25-OH-vitamin D (25-OH-vitD), which occur in more advanced stages of the disease.

Sign in / Sign up

Export Citation Format

Share Document